An open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients with locally advanced or metastatic HER2 negative and triple-negative breast cancer

Trial Profile

An open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients with locally advanced or metastatic HER2 negative and triple-negative breast cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Eribulin (Primary) ; PQR 309 (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors PIQUR Therapeutics
  • Most Recent Events

    • 20 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 30 Mar 2016 Status changed from planning to not yet recruiting as per ClinicalTrials.gov record.
    • 19 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top